Ultragenyx granted FDA priority review for rare metabolic disorder gene therapy
Source: SeekingAlpha
2026-02-23 10:59:56 ET
More on Ultragenyx Pharmaceutical
- Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript
- Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline
- Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Ultragenyx falls as guidance trails consensus amid job cuts
- Ultragenyx Pharmaceutical GAAP EPS of -$1.29 misses by $0.16, revenue of $207M beats by $5.14M
Read the full article on Seeking Alpha
For further details see:
Ultragenyx granted FDA priority review for rare metabolic disorder gene therapy
Ultragenyx Pharmaceutical Inc.
NASDAQ: RARE
RARE Trading
9.97% G/L:
$22.73 Last:
996,923 Volume:
$21.40 Open:
RARE Latest News
February 23, 2026 08:30:00 am
Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
February 12, 2026 04:01:00 pm
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
RARE Stock Data
$2,352,123,132
91,171,303
0.09%
84
N/A
Biotechnology & Life Sciences
Healthcare
US
Novato
